Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 356

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 356
---
 nature of polygenic risk research, and the possibility of overestimating or underestimating disease risk in individuals. Moreover, environmental and lifestyle factors, which PRS alone cannot account for, also play a significant role in disease development, underscoring the importance of a holistic approach when interpreting PRS results. At present, we have compiled PRS for breast cancer, prostate cancer, coronary artery diseases (CAD), and type II diabetes. In Argentina, we offer Rewell as a business -to - business-to -consumerservice, commercialized through select laboratories and partners. Customers purchase a “Complete Profile Kit,” which includes materials and instruction for collecting saliva and stool samples. Once their samples are collected, samples are transported for processing to our Argentine Wet -Lab, which we lease from CIBIC. Once processed, customers can view their DNA and gut microbiome test results either on our secure and proprietary digital platform or as a report. The results are processed using our bioinformatics pipeline, which incorporates our proprietary machine learning models and integrates them with our standard and proprietary databases. Results are categorized into sections such as nutrition, ancestry, health and prevention, immunity, among others, and are available for download and sharing. Customers are also given the option of allowing us to utilize their de -identifieddata to support our AI research and tool development, with most opting in. This data is integrated with third party data, allowing us to develop additional biomarkers for lifelong updates and enabling the future expansion of AI applications. To protect sensitive customer data used in research, we enforce security protocols including role -basedaccess controls, multi -factorauthentication, data encryption at rest and in transit, and data anonymization and pseudonymization prior to AI training and compliance checks. Health Management & Telemedicine Health management is a key component of Rewell’s value proposition. Rewell initially provided one -on-oneonline sessions with certified nutrigenetic specialists who hold degrees in nutrition and nutrigenomics. In early 2025, we transitioned our Rewell distribution strategy from a direct -to-consumerto a business -to-business-to-consumermodel. 181 As part of this transition, we seek to develop AI Agents to scale our health management and telemedicine component, leveraging insights and methodologies developed during the initial phase that contained one -on-onesessions with specialists. The objective of these sessions was to help users interpret their results and create personalized nutrition and lifestyle plans based on their health goal. These sessions aimed to review the most significant outcomes of the Rewell report